Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Thursday. The brokerage set a “hold” rating on the medical research company’s stock.

A number of other research firms also recently issued reports on CTSO. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Tuesday, May 7th. B. Riley reissued a “buy” rating and set a $3.00 price target on shares of Cytosorbents in a research report on Wednesday, May 15th.

Cytosorbents Stock Performance

CTSO stock opened at $0.70 on Thursday. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $4.29. The company has a quick ratio of 1.21, a current ratio of 1.49 and a debt-to-equity ratio of 0.10. The business’s fifty day simple moving average is $0.86 and its two-hundred day simple moving average is $0.99. The firm has a market cap of $38.18 million, a price-to-earnings ratio of -1.19 and a beta of 0.61.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. The business had revenue of $9.79 million for the quarter, compared to the consensus estimate of $9.78 million. During the same quarter in the prior year, the company earned ($0.17) EPS. Analysts predict that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

Institutional investors have recently added to or reduced their stakes in the stock. Key Client Fiduciary Advisors LLC boosted its position in Cytosorbents by 188.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 22,557 shares in the last quarter. Raymond James & Associates purchased a new stake in Cytosorbents in the fourth quarter valued at about $56,000. CM Management LLC raised its stake in Cytosorbents by 98.8% in the first quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after buying an additional 410,000 shares during the last quarter. Sargent Investment Group LLC raised its stake in Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after buying an additional 51,699 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its stake in Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after buying an additional 299,103 shares during the last quarter. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.